Lantern Pharma Inc. Manufacturing Costs
Lantern Pharma Inc. (LTRN) reported Manufacturing Costs of $804.40 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ManufacturingCosts · last filed 2026-05-15
- Lantern Pharma Inc. manufacturing costs for the quarter ending 2026-03-31 was $804.40K, a 62.17% decline year-over-year.
- Lantern Pharma Inc. manufacturing costs for the quarter ending 2025-12-31 was $1.85M, a 39.84% decline year-over-year.
- Lantern Pharma Inc. manufacturing costs for the quarter ending 2025-09-30 was $1.44M, a 41.70% decline year-over-year.
- Lantern Pharma Inc. manufacturing costs for the quarter ending 2025-06-30 was $1.95M, a 28.72% decline year-over-year.
- Lantern Pharma Inc. manufacturing costs for fiscal 2025 was $7.37M, a 35.39% decline from fiscal 2024.
- Lantern Pharma Inc. manufacturing costs for fiscal 2024 was $11.40M, a 34.86% increase from fiscal 2023.
- Lantern Pharma Inc. manufacturing costs for fiscal 2023 was $8.45M.
| Period end | Manufacturing Costs 3 month | Manufacturing Costs 3 month as first filed | Manufacturing Costs 6 month | Manufacturing Costs 9 month | Manufacturing Costs 12 month | Manufacturing Costs 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-03-31 | $804.40K 10-Q · filed 2026-05-15 | $2.66M derived: sum of 2 quarters · filed 2026-05-15 | $4.10M derived: sum of 3 quarters · filed 2026-05-15 | $6.04M derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2025-12-31 | $1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $3.29M derived: sum of 2 quarters · filed 2026-03-30 | $5.24M derived: sum of 3 quarters · filed 2026-03-30 | $7.37M 10-K · filed 2026-03-30 | ||
| 2025-09-30 | $1.44M 10-Q · filed 2025-11-12 | $3.39M derived: sum of 2 quarters · filed 2025-11-12 | $5.51M 10-Q · filed 2025-11-12 | $8.59M derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2025-06-30 | $1.95M 10-Q · filed 2025-08-13 | $4.07M 10-Q · filed 2025-08-13 | $7.15M derived: sum of 3 quarters · filed 2026-05-15 | $9.62M derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2025-03-31 | $2.13M 10-Q · filed 2026-05-15 | $2.13M 10-Q · filed 2025-05-15 | $5.20M derived: sum of 2 quarters · filed 2026-05-15 | $7.68M derived: sum of 3 quarters · filed 2026-05-15 | $10.41M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $5.55M derived: sum of 2 quarters · filed 2026-03-30 | $8.28M derived: sum of 3 quarters · filed 2026-03-30 | $11.40M 10-K · filed 2026-03-30 | $11.40M 10-K · filed 2025-03-27 | |
| 2024-09-30 | $2.48M 10-Q · filed 2025-11-12 | $5.21M derived: sum of 2 quarters · filed 2025-11-12 | $8.32M 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $2.73M 10-Q · filed 2025-08-13 | $5.85M 10-Q · filed 2025-08-13 | ||||
| 2024-03-31 | $3.12M 10-Q · filed 2025-05-15 | |||||
| 2023-12-31 | $8.45M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |